Works matching AU Xing, Puyuan

Results: 86

First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes.

Published in:

Thoracic Cancer, 2025, v. 16, n. 11, p. 1, doi. 10.1111/1759-7714.70095

By:

You, Mengxing;
Wu, Lige;
Liu, Jiayu;
Yuan, Hanqi;
Wang, Zihe;
Hao, Xuezhi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study.

Published in:

Oncologist, 2025, v. 30, n. 5, p. 1, doi. 10.1093/oncolo/oyaf079

By:

Xing, Puyuan;
Pu, Xingxiang;
Zhou, Yu;
Liu, Ziling;
Yao, Yu;
Liu, Jiayu;
Wang, Shouzheng;
Hu, Ying;
Li, Junling;
Wu, Lin

Publication type:

Article

Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.

Published in:

2018

By:

Qiu, Tian;
Li, Weihua;
Zhang, Tongtong;
Xing, Puyuan;
Huang, Wenting;
Wang, Bingning;
Chu, Lixia;
Guo, Lei;
Liu, Xiuyun;
Li, Yan;
Ying, Jianming;
Li, Junling

Publication type:

journal article

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.

Published in:

2019

By:

Mu, Yuxin;
Hao, Xuezhi;
Yang, Ke;
Ma, Di;
Wang, Shouzheng;
Xu, Ziyi;
Li, Junling;
Xing, Puyuan

Publication type:

journal article

Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.

Published in:

2019

By:

Xing, Puyuan;
Wang, Shouzheng;
Wang, Qiang;
Ma, Di;
Hao, Xuezhi;
Wang, Mengzhao;
Wang, Yan;
Shan, Li;
Xin, Tao;
Liang, Li;
Liang, Hongge;
Du, Yang;
Zhang, Zhaohui;
Li, Junling

Publication type:

journal article

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency.

Published in:

Cell Communication & Signaling, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12964-023-01065-9

By:

Sun, Dantong;
Feng, Feiyue;
Teng, Fei;
Xie, Tongji;
Wang, Jinsong;
Xing, Puyuan;
Qian, Haili;
Li, Junling

Publication type:

Article

Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.

Published in:

2022

By:

Xing, Puyuan;
Zhao, Qian;
Zhang, Li;
Wang, Hanping;
Huang, Dingzhi;
Hu, Pei;
Sun, Yinghui;
Shi, Yuankai

Publication type:

journal article

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).

Published in:

BMC Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12916-022-02470-6

By:

Yang, Guangjian;
Xu, Haiyan;
Yang, Yaning;
Zhang, Shuyang;
Xu, Fei;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan;
Hu, Xingsheng;
Liu, Yutao;
Wang, Lin;
Lin, Lin;
Wang, Zhijie;
Duan, Jianchun;
Wang, Jie;
Wang, Yan

Publication type:

Article

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.

Published in:

Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 11, p. 3081, doi. 10.1007/s00432-021-03901-2

By:

Xu, Ziyi;
Hao, Xuezhi;
Yang, Ke;
Wang, Qi;
Wang, Jing;
Lin, Lin;
Teng, Fei;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC.

Published in:

Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 5, p. 1137, doi. 10.1007/s00432-021-03681-9

By:

Zhang, Yujuan;
Men, Yu;
Wang, Jianyang;
Xing, Puyuan;
Zhao, Jun;
Li, Junling;
Xu, Danfei;
Hui, Zhouguang;
Cui, Wei

Publication type:

Article

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.

Published in:

Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 9, p. 2427, doi. 10.1007/s00432-020-03239-1

By:

Mu, Yuxin;
Hao, Xuezhi;
Xing, Puyuan;
Hu, Xingsheng;
Wang, Yan;
Li, Teng;
Zhang, Jinyao;
Xu, Ziyi;
Li, Junling

Publication type:

Article

Artificial neural network systems to predict the response to sintilimab in squamous-cell non-small-cell lung cancer based on data of ORIENT-3 study.

Published in:

Cancer Immunology, Immunotherapy, 2025, v. 74, n. 1, p. 1, doi. 10.1007/s00262-024-03886-0

By:

Xie, Tongji;
Fan, Guangyu;
Tang, Le;
Xing, Puyuan;
Shi, Yuankai

Publication type:

Article

Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 3, p. 1, doi. 10.1007/s00262-024-03631-7

By:

Tan, Qiaoyun;
Gao, Ruyun;
Zhang, Xiaomei;
Yang, Jianliang;
Xing, Puyuan;
Yang, Sheng;
Wang, Dan;
Wang, Guibing;
Wang, Shasha;
Yao, Jiarui;
Zhang, Zhishang;
Tang, Le;
Yu, Xiaobo;
Han, Xiaohong;
Shi, Yuankai

Publication type:

Article

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1681, doi. 10.1007/s00262-021-03106-z

By:

Tan, Qiaoyun;
Dai, Liyuan;
Wang, Yanrong;
Liu, Shuxia;
Liang, Te;
Luo, Rongrong;
Wang, Shasha;
Lou, Ning;
Chen, Haizhu;
Zhou, Yu;
Zhong, Qiaofeng;
Yang, Jianliang;
Xing, Puyuan;
Hu, Xingsheng;
Liu, Yutao;
Zhou, Shengyu;
Yao, Jiarui;
Wu, Di;
Zhang, Zhishang;
Tang, Le

Publication type:

Article

Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.

Published in:

Molecular & Clinical Oncology, 2014, v. 2, n. 1, p. 87, doi. 10.3892/mco.2013.199

By:

YANG LUO;
YUANKAI SHI;
PUYUAN XING;
LIN WANG;
YUN FENG;
XIAOHONG HAN;
XIAOHUI HE

Publication type:

Article

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.

Published in:

BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10676-x

By:

Xu, Ziyi;
Hao, Xuezhi;
Wang, Qi;
Yang, Ke;
Li, Junling;
Xing, Puyuan

Publication type:

Article

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer.

Published in:

Molecular Medicine, 2021, v. 27, n. 1, p. 1, doi. 10.1186/s10020-021-00400-5

By:

Sun, Dantong;
Teng, Fei;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.

Published in:

Hematology, 2016, v. 21, n. 9, p. 536, doi. 10.1080/10245332.2016.1152084

By:

Jia, Bo;
Hu, Shaoxuan;
Yang, Jianliang;
Zhou, Shengyu;
Liu, Peng;
Qin, Yan;
Gui, Lin;
Yang, Sheng;
Lin, Hua;
Zhang, Changgong;
Xing, Puyuan;
Wang, Lin;
Dong, Mei;
Zhou, Liqiang;
Sun, Yan;
He, Xiaohui;
Shi, Yuankai

Publication type:

Article

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study.

Published in:

Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221082339

By:

Yang, Guangjian;
Yang, Yaning;
Liu, Runze;
Li, Weihua;
Xu, Haiyan;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan;
Zhang, Shuyang;
Ai, Xin;
Xu, Fei;
Wang, Yan

Publication type:

Article

Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing.

Published in:

Expert Review of Anticancer Therapy, 2024, v. 24, n. 3/4, p. 183, doi. 10.1080/14737140.2024.2334807

By:

Xu, Ziyi;
Li, Yan;
Wang, Lin;
Hao, Xuezhi;
Ying, Jianming;
Li, Junling;
Xing, Puyuan

Publication type:

Article

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.976731

By:

Haiyan Xu;
Guangjian Yang;
Runze Liu;
Yaning Yang;
Weihua Li;
Junling Li;
Xuezhi Hao;
Puyuan Xing;
Yan Wang

Publication type:

Article

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer.

Published in:

Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00603

By:

Mu, Yuxin;
Yang, Ke;
Hao, Xuezhi;
Wang, Yan;
Wang, Lin;
Liu, Yutao;
Lin, Lin;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma.

Published in:

Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00556

By:

Han, Xiaohong;
Tan, Qiaoyun;
Yang, Sheng;
Li, Junling;
Xu, Jianping;
Hao, Xuezhi;
Hu, Xingsheng;
Xing, Puyuan;
Liu, Yutao;
Lin, Lin;
Gui, Lin;
Qin, Yan;
Yang, Jianliang;
Liu, Peng;
Wang, Xingyuan;
Dai, Wumin;
Lin, Dongmei;
Lin, Hua;
Shi, Yuankai

Publication type:

Article

Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy.

Published in:

Journal of Biomedical Science, 2024, v. 31, n. 1, p. 1, doi. 10.1186/s12929-024-01004-x

By:

Sun, Dantong;
Qian, Haili;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma.

Published in:

Cancer (0008543X), 2023, v. 129, n. 24, p. 3873, doi. 10.1002/cncr.34967

By:

Wang, Shouzheng;
Xie, Tongji;
Li, Yan;
Guo, Lei;
Ying, Jianming;
Wang, Yan;
Hao, Xuezhi;
Wang, Xingyuan;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.

Published in:

2017

By:

Huang, Yu;
Yang, Jianliang;
Liu, Peng;
Zhou, Shengyu;
Gui, Lin;
He, Xiaohui;
Qin, Yan;
Zhang, Changgong;
Yang, Sheng;
Xing, Puyuan;
Sun, Yan;
Shi, Yuankai

Publication type:

journal article

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.

Published in:

BMC Immunology, 2018, v. 19, n. 1, p. N.PAG, doi. 10.1186/s12865-018-0249-9

By:

Xing, Puyuan;
Wang, Hongyu;
Yang, Sheng;
Han, Xiaohong;
Sun, Yan;
Shi, Yuankai

Publication type:

Article

Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas.

Published in:

Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-01981-3

By:

Li, Yan;
Xie, Tongji;
Wang, Shouzheng;
Yang, Lin;
Hao, Xuezhi;
Wang, Yan;
Hu, Xingsheng;
Wang, Lin;
Li, Junling;
Ying, Jianming;
Xing, Puyuan

Publication type:

Article

Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain‐only relapse versus synchronous extracranial relapse.

Published in:

Cancer Medicine, 2023, v. 12, n. 11, p. 12495, doi. 10.1002/cam4.5961

By:

Xu, Fei;
Li, Junling;
Xing, Puyuan;
Liu, Yutao;
Wang, Yan

Publication type:

Article

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study.

Published in:

Cancer Medicine, 2019, v. 8, n. 13, p. 5823, doi. 10.1002/cam4.2420

By:

Yang, Guangjian;
Ma, Di;
Xu, Haiyan;
Yang, Lu;
Li, Junling;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Yan

Publication type:

Article

A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.

Published in:

Cancer Medicine, 2016, v. 5, n. 6, p. 1116, doi. 10.1002/cam4.689

By:

Mo, Hongnan;
Hao, Xuezhi;
Liu, Yutao;
Wang, Lin;
Hu, Xingsheng;
Xu, Jianping;
Yang, Sheng;
Xing, Puyuan;
Shi, Youwu;
Jia, Bo;
Wang, Yan;
Li, Junling;
Wang, Hongyu;
Wang, Ziping;
Sun, Yan;
Shi, Yuankai

Publication type:

Article

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression.

Published in:

Cancer Management & Research, 2022, v. 14, p. 1891, doi. 10.2147/CMAR.S363446

By:

Xu, Ziyi;
Teng, Fei;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.

Published in:

Cancer Management & Research, 2022, v. 14, p. 863, doi. 10.2147/CMAR.S346173

By:

Xu, Ziyi;
Hao, Xuezhi;
Wang, Qi;
Wang, Jing;
Yang, Ke;
Wang, Shouzheng;
Teng, Fei;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study.

Published in:

Cancer Management & Research, 2019, v. 11, p. 9243, doi. 10.2147/CMAR.S221434

By:

Mu, Yuxin;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Yan;
Li, Junling

Publication type:

Article

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences.

Published in:

Thoracic Cancer, 2022, v. 13, n. 22, p. 3105, doi. 10.1111/1759-7714.14659

By:

Xu, Fei;
Chen, Heng‐chi;
Xu, Haiyan;
Li, Junling;
Hao, Xuezhi;
Xing, Puyuan;
Ying, Jianming;
Wang, Yan

Publication type:

Article

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.

Published in:

Thoracic Cancer, 2022, v. 13, n. 15, p. 2201, doi. 10.1111/1759-7714.14545

By:

Li, Yan;
Xu, Ziyi;
Wang, Shouzheng;
Zhu, Yixiang;
Ma, Di;
Mu, Yuxin;
Ying, Jianming;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.

Published in:

Thoracic Cancer, 2022, v. 13, n. 4, p. 557, doi. 10.1111/1759-7714.14298

By:

Fei Teng;
Puyuan Xing;
Ke Yang;
Lizhen Gao;
Zhongqiu Tian;
Junling Li

Publication type:

Article

ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.

Published in:

Thoracic Cancer, 2022, v. 13, n. 3, p. 338, doi. 10.1111/1759-7714.14249

By:

Hu, Chunfang;
Dong, Jiyan;
Liu, Li;
Liu, Jingbo;
Sun, Xujie;
Teng, Fei;
Wang, Xin;
Ying, Jianming;
Li, Junling;
Xing, Puyuan;
Yang, Lin

Publication type:

Article

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.

Published in:

Thoracic Cancer, 2022, v. 13, n. 1, p. 107, doi. 10.1111/1759-7714.14232

By:

Zou, Zihua;
Hao, Xuezhi;
Zhang, Cuiying;
Li, Haojing;
Dong, Guilan;
Peng, Yumei;
Ma, Kewei;
Guo, Ye;
Shan, Li;
Zhang, Yan;
Liang, Li;
Gu, Yangchun;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Published in:

Thoracic Cancer, 2021, v. 12, n. 21, p. 2924, doi. 10.1111/1759-7714.14156

By:

Li, Teng;
Wang, Shouzheng;
Ying, Jianming;
Wang, Yan;
Hu, Xingsheng;
Hao, Xuezhi;
Xu, Ziyi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy.

Published in:

Thoracic Cancer, 2021, v. 12, n. 20, p. 2825, doi. 10.1111/1759-7714.14113

By:

Xing, Puyuan;
Wang, Mengzhao;
Zhao, Jun;
Zhong, Wei;
Chi, Yujia;
Xu, Ziyi;
Li, Junling

Publication type:

Article

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.

Published in:

Thoracic Cancer, 2021, v. 12, n. 19, p. 2585, doi. 10.1111/1759-7714.14144

By:

Wang, Shouzheng;
Xie, Tongji;
Hao, Xuezhi;
Wang, Yan;
Hu, Xingsheng;
Wang, Lin;
Li, Yan;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC).

Published in:

Thoracic Cancer, 2021, v. 12, n. 17, p. 2360, doi. 10.1111/1759-7714.14078

By:

Xu, Ziyi;
Li, Teng;
Hu, Xingsheng;
Hao, Xuezhi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

Published in:

Thoracic Cancer, 2021, v. 12, n. 16, p. 2233, doi. 10.1111/1759-7714.14057

By:

Xu, Ziyi;
Hao, Xuezhi;
Lin, Lin;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.

Published in:

Thoracic Cancer, 2021, v. 12, n. 1, p. 40, doi. 10.1111/1759-7714.13705

By:

Wei, Jiacong;
Liu, Li;
Guo, Yiying;
Zhang, Jinyao;
Wang, Xin;
Dong, Jiyan;
Xing, Puyuan;
Ying, Jianming;
Yang, Lin;
Li, Junling

Publication type:

Article

Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection.

Published in:

Thoracic Cancer, 2020, v. 11, n. 10, p. 2782, doi. 10.1111/1759-7714.13591

By:

Guo, Yiying;
Yang, Lin;
Liu, Li;
Wei, Jiacong;
Teng, Fei;
Zhang, Jinyao;
Zhu, Yixiang;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations.

Published in:

Thoracic Cancer, 2019, v. 10, n. 6, p. 1461, doi. 10.1111/1759-7714.13095

By:

Wang, Shouzheng;
Xing, Puyuan;
Yang, Ke;
Hao, Xuezhi;
Ma, Di;
Mu, Yuxin;
Li, Junling

Publication type:

Article

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib.

Published in:

Thoracic Cancer, 2019, v. 10, n. 5, p. 1213, doi. 10.1111/1759-7714.13071

By:

Ma, Di;
Zhang, Yan;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Mengzhao;
Wang, Yan;
Shan, Li;
Xin, Tao;
Liang, Hongge;
Du, Yang;
Zhang, Zhaohui;
Liang, Li;
Li, Junling

Publication type:

Article

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance.

Published in:

Thoracic Cancer, 2019, v. 10, n. 5, p. 1096, doi. 10.1111/1759-7714.13050

By:

Xu, Haiyan;
Yang, Guangjian;
Yang, Lu;
Yang, Yaning;
Ma, Di;
Li, Junling;
Hao, Xuezhi;
Xing, Puyuan;
Wang, Yan

Publication type:

Article

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer.

Published in:

Thoracic Cancer, 2018, v. 9, n. 12, p. 1716, doi. 10.1111/1759-7714.12886

By:

Xing, Puyuan;
Mu, Yuxin;
Wang, Yan;
Hao, Xuezhi;
Zhu, Yixiang;
Hu, Xingsheng;
Wang, Hongyu;
Liu, Peng;
Lin, Lin;
Wang, Zhijie;
Li, Junling

Publication type:

Article